Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.23 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their clinical programs.
Management did not provide specific updates on revenue or guidance.
The focus remains on ongoing clinical trials and product development.
Viking Therapeutics reported a loss of $0.23 per share for Q1 2017, with no revenue figures disclosed. The stock reacted negatively, dropping 0.72%. The lack of guidance and specific revenue details may have contributed to investor uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Hecla Mining Company